Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or ... Read more
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A ... Read more
MorphoSys is asking the U.S. Food and Drug Administration (FDA) to approve its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more
Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have high ... Read more
Patients with cutaneous T-cell lymphoma (CTCL) who for some reason discontinue their systemic treatments require more monthly emergency room visits, hospital admissions, and longer inpatient stays than those who continue ... Read more
The European Commission has approved the used of Adcetris (brentuximab vedotin) in combination with standard chemotherapy for the initial treatment of advanced CD30-positive Hodgkin’s lymphoma patients in the European Union, Norway, Liechtenstein and Iceland. The approval, ... Read more
Adding Rituxan (rituximab) to standard first-line chemotherapy did not improve disease outcomes for people with primary central nervous system (CNS) lymphoma in a Phase 3 clinical trial, results show. The ... Read more
Survivors of childhood Hodgkin’s lymphoma are 14 times more likely to develop a subsequent solid tumor than the general population, and this risk remains high for several decades post-diagnosis, a ... Read more
A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors. The trial, so far being conducted ... Read more